Johnson & Johnson (NYSE:JNJ) issued an update on its FY 2019 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.58. The company issued revenue guidance of $80.4-81.2 billion, compared to the consensus revenue estimate of $81.05 billion.Johnson & Johnson also updated its FY19 guidance to $8.53-8.63 EPS.
NYSE:JNJ opened at $138.02 on Wednesday. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20. The firm has a market capitalization of $370.29 billion, a P/E ratio of 16.87, a PEG ratio of 2.21 and a beta of 0.68.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The business had revenue of $20.02 billion during the quarter, compared to analysts’ expectations of $19.55 billion. During the same period last year, the business earned $2.06 earnings per share. The firm’s revenue was up .1% on a year-over-year basis. As a group, sell-side analysts anticipate that Johnson & Johnson will post 8.58 EPS for the current year.
Several equities analysts recently weighed in on JNJ shares. Zacks Investment Research cut shares of Johnson & Johnson from a buy rating to a sell rating in a research note on Tuesday, December 18th. Morgan Stanley set a $140.00 target price on shares of Johnson & Johnson and gave the company a hold rating in a research note on Thursday, December 20th. Citigroup decreased their target price on shares of Johnson & Johnson from $148.00 to $139.00 and set a neutral rating for the company in a research note on Wednesday, January 2nd. Wells Fargo & Co reaffirmed an outperform rating and set a $152.00 price objective (down from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Finally, Barclays reaffirmed an equal weight rating and set a $135.00 price objective (down from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $143.58.
Hedge funds have recently added to or reduced their stakes in the business. Crewe Advisors LLC boosted its position in Johnson & Johnson by 75.0% during the fourth quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock worth $45,000 after purchasing an additional 150 shares during the period. Ruggie Capital Group boosted its position in shares of Johnson & Johnson by 342.5% in the fourth quarter. Ruggie Capital Group now owns 469 shares of the company’s stock valued at $60,000 after acquiring an additional 363 shares during the period. Litman Gregory Asset Management LLC boosted its position in shares of Johnson & Johnson by 105.9% in the fourth quarter. Litman Gregory Asset Management LLC now owns 486 shares of the company’s stock valued at $63,000 after acquiring an additional 250 shares during the period. Financial Gravity Companies Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $82,000. Finally, Next Capital Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $83,000. 67.32% of the stock is owned by hedge funds and other institutional investors.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: How to Use the New Google Finance Tool
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.